Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Prospective observational single-center study in which the impact of anti-TNF biological treatment on the humoral response after complete vaccination against SARS-COV2 in patients with inflammatory bowel disease is analyzed.
The first objective is to compare the seroconversion rate after full vaccination against SARS-COV2 in patients with IBD treated with anti-TNF drugs versus patients treated with Ustekinumab / Vedolizumab and patients without immunosuppressive treatment.
The Patients included in the study belong to the health area of the Virgen Macarena University Hospital who meet the following inclusion criteria and none for exclusion.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be of legal age (\> 18 years).
Diagnosis of inflammatory bowel disease (Crohn's Disease or Ulcerative Colitis).
Complete vaccination schedule (one or two doses depending on previous SARS-Cov2 infection) between one and four months prior to the determination of anti-SARS-Cov2 antibodies.
Treatment with biological therapy for at least 6 weeks prior to the time of vaccination for the group of patients treated with biological drugs.
You may not be if
Last vaccination dose more than four months ago from the determination of antibodies against SARS-Cov2.
